NVS
Price
$98.07
Change
-$0.52 (-0.53%)
Updated
Dec 13, 12:02 PM (EDT)
49 days until earnings call
SNY
Price
$47.00
Change
-$0.99 (-2.06%)
Updated
Dec 12, 04:59 PM (EDT)
48 days until earnings call
Ad is loading...

NVS vs SNY

Header iconNVS vs SNY Comparison
Open Charts NVS vs SNYBanner chart's image
Novartis AG
Price$98.07
Change-$0.52 (-0.53%)
Volume$7.77K
CapitalizationN/A
Sanofi ADS
Price$47.00
Change-$0.99 (-2.06%)
Volume$86.89K
CapitalizationN/A
NVS vs SNY Comparison Chart
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. SNY commentary
Dec 13, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and SNY is a Buy.

COMPARISON
Comparison
Dec 13, 2024
Stock price -- (NVS: $98.59 vs. SNY: $46.99)
Brand notoriety: NVS and SNY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 91% vs. SNY: 100%
Market capitalization -- NVS: $197.93B vs. SNY: $122.61B
NVS [@Pharmaceuticals: Major] is valued at $197.93B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileSNY’s FA Score has 2 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • SNY’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 5 bullish TA indicator(s).

  • NVS’s TA Score: 4 bullish, 4 bearish.
  • SNY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SNY is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а -3.83% price change this week, while SNY (@Pharmaceuticals: Major) price change was -3.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.78%. For the same industry, the average monthly price growth was -5.03%, and the average quarterly price growth was -1.46%.

Reported Earning Dates

NVS is expected to report earnings on Jan 31, 2025.

SNY is expected to report earnings on Jan 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.78% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($198B) has a higher market cap than SNY($123B). NVS has higher P/E ratio than SNY: NVS (23.38) vs SNY (20.80). NVS YTD gains are higher at: 1.374 vs. SNY (-1.504). NVS has higher annual earnings (EBITDA): 18.3B vs. SNY (12.6B). NVS has more cash in the bank: 14B vs. SNY (8.98B). SNY has less debt than NVS: SNY (18.4B) vs NVS (26.3B). NVS (46.7B) and SNY (46.4B) have equivalent revenues.
NVSSNYNVS / SNY
Capitalization198B123B161%
EBITDA18.3B12.6B145%
Gain YTD1.374-1.504-91%
P/E Ratio23.3820.80112%
Revenue46.7B46.4B101%
Total Cash14B8.98B156%
Total Debt26.3B18.4B143%
FUNDAMENTALS RATINGS
NVS vs SNY: Fundamental Ratings
NVS
SNY
OUTLOOK RATING
1..100
5363
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
2555
SMR RATING
1..100
2280
PRICE GROWTH RATING
1..100
6261
P/E GROWTH RATING
1..100
9031
SEASONALITY SCORE
1..100
5045

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (9) in the Pharmaceuticals Major industry is in the same range as NVS (12). This means that SNY’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (25) in the Pharmaceuticals Major industry is in the same range as SNY (55). This means that NVS’s stock grew similarly to SNY’s over the last 12 months.

NVS's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (80). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.

SNY's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as NVS (62). This means that SNY’s stock grew similarly to NVS’s over the last 12 months.

SNY's P/E Growth Rating (31) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (90). This means that SNY’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSSNY
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 1 day ago
52%
Momentum
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
52%
MACD
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
53%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
38%
Bearish Trend 1 day ago
42%
Advances
ODDS (%)
Bullish Trend 15 days ago
46%
Bullish Trend 19 days ago
53%
Declines
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 1 day ago
49%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
53%
Aroon
ODDS (%)
Bearish Trend 1 day ago
29%
Bearish Trend 1 day ago
44%
View a ticker or compare two or three
Ad is loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ILPT3.640.02
+0.55%
Industrial Logistics Properties Trust
BILI20.250.02
+0.10%
Bilibili
LVS53.80-0.65
-1.19%
Las Vegas Sands Corp
HE10.07-0.15
-1.47%
Hawaiian Electric Industries
CLDI1.87-0.03
-1.58%
Calidi Biotherapeutics

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
-2.08%
SNYNF - SNY
61%
Loosely correlated
-1.30%
NVS - SNY
40%
Loosely correlated
-0.58%
AZN - SNY
37%
Loosely correlated
-0.68%
JNJ - SNY
35%
Loosely correlated
-0.27%
GSK - SNY
32%
Poorly correlated
-0.81%
More